Terbinafine ( DrugBank: Terbinafine )


3 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease1
97Ulcerative colitis1
271Ankylosing spondylitis1

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05049525
(ClinicalTrials.gov)
January 202225/8/2021Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's DiseaseEvaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Not Responding Adequately to Current TherapyCrohn's Disease;Inflammatory Bowel DiseasesDrug: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.;Drug: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.Montreal Heart InstituteNULLNot yet recruiting18 Years65 YearsAll68Phase 2NULL

97. Ulcerative colitis


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02606032
(ClinicalTrials.gov)
May 201613/11/2015Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative ColitisRandomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative ColitisUlcerative ColitisDrug: Metronidazole;Drug: Doxycycline;Drug: Terbinafine;Drug: PlaceboHamilton Health Sciences CorporationHamilton Academic Health Sciences OrganizationCompleted18 YearsN/AAll75Phase 2Canada

271. Ankylosing spondylitis


Clinical trials : 563 Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05119712
(ClinicalTrials.gov)
March 9, 20213/11/2021Terbinafine Treatment of Axial SpondyloarthropathyTerbinafine Treatment of Axial SpondyloarthropathyAnkylosing Spondylitis;Axial Spondyloarthritis;Psoriatic Spondylitis;Spondylitis Secondary to Inflammatory Bowel Disease;Axial SpondyloarthopathyDrug: Terbinafine Tablets;Diagnostic Test: Laboratory TestingOregon Health and Science UniversityThe Malassezia FoundationRecruiting18 YearsN/AAll20Early Phase 1United States